Trials / Completed
CompletedNCT01633372
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
An Open-Label, Multiple Simon 2-Stage Study of Itacitinib Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | itacitinib |
Timeline
- Start date
- 2012-07-16
- Primary completion
- 2013-12-31
- Completion
- 2021-06-29
- First posted
- 2012-07-04
- Last updated
- 2021-08-30
Locations
22 sites across 3 countries: United States, Australia, Canada
Source: ClinicalTrials.gov record NCT01633372. Inclusion in this directory is not an endorsement.